TARS Q1 2022 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$539,000-98.4% YoY

Gross Profit

$506,00093.9% margin

Operating Income

-$20M-3621.7% margin

Net Income

-$20M-3754.7% margin

EPS (Diluted)

$-0.98

QoQ Revenue Growth

+59.5%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$181M

Total Liabilities

$32M

Stockholders' Equity

$149M

Cash & Equivalents

$175M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$539,000	$33M	-98.4%
Gross Profit	$506,000	$32M	-98.4%
Operating Income	-$20M	$11M	-282.2%
Net Income	-$20M	$10M	-296.8%

Revenue Segments

Collaboration

$539,00094%

License And Collaboration

$33,0006%